Final FDA approval of vagus nerve stimulation as a treatment for chronic or recurrent therapy-resistant depression to be issued in Might. Psychiatrists will then officially be in a position to prescribe this outstanding, existence altering treatment for patients.

On April 7th, 2005, the producer of the vagus nerve stimulator( Cyberonics, Inc.) announced that it had been notified by the U.S. Food and Drug Administration(FDA) that 1 the couple of remaining circumstances of final FDA approval had been happy. Cyberonics also announced that it was very assured that the two remaining circumstances will be expeditously happy and that final FDA approval will be issued in Might.

Robert P. (&quotSkip&quot) Cummins, Cyberonics’ Chairman of the Board and Chief Executive Officer commented: &quotThis main stage forward in the direction of the accomplishment of Cyberonics’ mission to enhance the lives of individuals touched by refractory epilepsy and therapy-resistant depression (TRD) would not have been feasible with out the timely, diligent, interactive and cooperative efforts of the entire Dallas District Workplace employees led by Michael Chappell, District Director, and the Cyberonics regulatory group. Cyberonics and CDRH carry on to make good progress in the direction of our goal of satisfying the remaining circumstances of final TRD approval.&quot

The official start of vagus nerve stimulation as a therapy for depression will consider location at the American Psychiatric Association’s Yearly Meeting at the World Congress Center in Atlanta from Might 21st to Might 25th. The Yearly Meeting will be attended by over twenty,000 psychiatrists.

Major depressive condition is 1 of the most prevalent and severe diseases in the U.S., affecting almost 19 million Americans every yr. Depression is the second leading trigger of disability for the general population and the leading trigger of disability for American ladies. Approximately twenty % of depressed Americans, or approximately four million individuals, experience chronic or recurrent therapy-resistant depression that has failed to respond to numerous antidepressant remedies. If approved, the VNS Therapy Program will be the initial implantable gadget-based therapy for depression and the initial therapy created, studied and labeled specifically for patients with therapy-resistant depression.

Vagus nerve stimulation will be the mainstream therapy for chronic or therapy-resistant depression. More than four million American suffer from chronic depression. The final FDA approval will be considered 1 of the main breakthroughs in health-related gadget history.

You can learn much more at http://www.VagusNerveStimulator.com. There is a totally free electronic newsletter to keep you up-to-day.

Charles Donovan was a patient in the FDA investigational trial of vagus nerve stimulation as a therapy for chronic or recurrent therapy-resistant depression. He was implanted with the vagus nerve stimulator in April of 2001. He chronicles his journey from the grips of depression many thanks to vagus nerve stimulation treatment in his book:

Out of the Black Hole: The Patient’s Guide to Vagus Nerve Stimulation and Depression

The book will be exhibited at the American Psychiatric Association’s Yearly Meeting in Might.

He is editor the http://www.VagusNerveStimulator.com Internet Site